1998 to 2022 Saw Rise in Number Seeking Assisted Death in Oregon
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Oct. 6, 2023 -- Over the 25 years that Oregon has offered assisted death, there have been shifts in the volume and sociodemographics of the patient population, according to a study published online Oct. 3 in BMJ Supportive & Palliative Care.
Claud Regnard, M.B.Ch.B., from St. Oswald's Hospice in Newcastle upon Tyne, England, and colleagues examined data on 2,454 assisted deaths included in annual reports on assisted deaths published by the Oregon Health Authority (1998 to 2022) to characterize trends.
The researchers found that the number of assisted deaths in Oregon increased from 16 in 1998 to 278 in 2022. Patients' insurance status changed from predominantly private (65 percent) to predominantly government support (79.5 percent) over time. Relatedly, there was an increase in patients feeling a burden and describing financial concerns as reasons for choosing an assisted death. The reported length of the physician-patient relationship declined from 18 weeks in 2010 to five weeks in 2022. The proportion of assisted deaths referred for psychiatric assessment remained low (1 percent). Data regarding complications, especially around decision-making, drug efficacy, and the nature of palliative care support, were missing or not collected.
"Oregon's changing trends in assisted dying require detailed prospective studies examining how socioeconomic factors influence the wish for an assisted death," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.